ClinicalTrials.gg
CompletedNCT04452981Updated Jan 16, 2024

Electrical Vestibular Nerve Stimulation (VeNS) as a Treatment for Insomnia

An interventional study of VeNS in Insomnia and Sleep Disturbance, sponsored by Neurovalens Ltd.. Completed at 2 sites in 2 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-01-16.

Sponsored by Neurovalens Ltd. · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
153
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 86 studies in Sleep Initiation and Maintenance Disorders with a site in Hong Kong — 31 open to participants now, 31 under way, none of them phase 3. Sleep Initiation and Maintenance Disorders · Hong Kong.

Enrollment
21st of 83
153 · median 90
Started
2022
with 10 others
No phase
81 of 86
27 open now
Registered
29th of 86
by date
Lead sponsor
1 of 86
Neurovalens Ltd.

Among the 86 studies in Sleep Initiation and Maintenance Disorders with a site in Hong Kong, this one is the 21st largest by enrollment of the 83 interventional ones that give a count, is one of 11 that started in 2022, is one of 81 with no phase, and was the 29th registered.

Sleep Initiation and Maintenance Disorders

2,738 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 735 are open to participants now.

Browse Sleep Initiation and Maintenance Disorders studies →

Open to participants now

31 of the 86 studies in Sleep Initiation and Maintenance Disorders with a site in Hong Kong are open now. Recruiting first, the newest first:

26 more — sign in →

All 31 open studies →

A study can be open while its sites in Hong Kong have not opened yet or have stopped. Only those recruiting at a site in Hong Kong →

Who these studies take

Of the 394 Sleep Initiation and Maintenance Disorders studies recruiting now, 156 (40%) set no upper age limit and 208 (53%) stop at 75 or younger; 61 take children under 18; 112 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 86 studies in Sleep Initiation and Maintenance Disorders with a site in Hong Kong, or all of them as a file.
02

Study summary

Insomnia is known to be one of the most common health concerns in in the general population and has been associated with several health consequences. Medications are known to be effective, and currently serve as the primary treatment for insomnia but their use is limited due to the risk of adverse events. Cognitive Behavioral Therapy (CBT-1) has also been shown to be effective and safer in the treatment of insomnia but presents its own limitations such as the time, cost, and training required. The relationship between vestibular stimulation and sleep continues to be explored, however its usefulness in the treatment of insomnia is still unknown. Vestibular stimulation itself has been shown to be safe across multiple populations. If vestibular stimulation is shown to be effective in the treatment of insomnia, it could serve as a safer alternative to medications. It could also require less cost, time, and training than CBT-1, providing a treatment option that is not only safe and effective, but broadly available to the general population. Consequently this trial seeks to evaluate the efficacy of non-invasive electrical vestibular nerve stimulation as a method of improving sleep quality and quantity, as compared to a sham control, in patients newly diagnosed with insomnia.

03

Conditions studied

  • Insomnia
  • Sleep Disturbance
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed
  2. Diagnosed insomnia with ISI of 15 or greater at screening
  3. Males or females
  4. 18-80 years of age inclusive on starting the study
  5. Ability and willingness to complete all study visits and procedures; in particular an agreement to engage with trying to use the device on a daily basis
  6. Agreement not to use prescription, or over the counter, sleep medications for the duration of the trial
  7. Agreement not to use sleep trackers for the duration of the study (e.g sleep app smart watches)
  8. Access to Wi-Fi (to connect iPod to internet)

Exclusion criteria

Exclusion Criteria

  1. History of skin breakdown, eczema or other dermatological condition (e.g. psoriasis) affecting the skin behind the ears (image from participant required).
  2. Previous diagnosis of infection or AIDS (HIV is known to cause a vestibular neuropathy which would prevent VeNS from working)
  3. Medication for insomnia (unless regime stable for last 3 months).
  4. A history of stroke or severe head injury (as defined by a head injury that required a craniotomy or endotracheal intubation). (In case this damaged the neurological pathways involved in vestibular stimulation).
  5. Presence of permanently implanted battery powered medical device or stimulator (e.g., pacemaker, implanted defibrillator, deep brain stimulator, vagal nerve stimulator etc.).
  6. Pregnancy.
  7. Previous use of any VeNS device
  8. Participation in other clinical trials sponsored by Neurovalens
  9. Have a member of the same household who is currently participating in this study.
  10. History of vestibular dysfunction or other inner ear disease as indicated by the following screening questions:
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
153 participants (actual)

Study arms

  • Active comparator
    Active

    The active device utilizes a technology termed vestibular nerve stimulation (VeNS). The device will be placed on the head in a manner analogous to headphones and will deliver a small electrical current to the skin behind the ears, over the mastoid processes. Participants will be advised to use the device at home for 1 hour per day.

    Device: VeNS

  • Sham comparator
    Sham

    The sham device looks identical to the active device and interacts with the app in a similar manner to the active device. It will apply some stimulation to a user for a limited period of time (30 seconds), before tapering down to zero over a further 20 seconds, thus creating the impression of an active device. The device will be placed on the head in a manner analogous to headphones with hydrogel electrodes placed over the mastoid processes. Participants will be advised to use the device at home for 1 hour per day.

    Device: VeNS

Interventions

  • DeviceVeNS

    The VeNS device utilizes a technology called galvanic vestibular stimulation (GVS) (sometimes termed vestibular nerve stimulation (VeNS)). The device will be placed on the head in a manner analogous to headphones and will deliver a small electrical current to the skin behind the ears, over the mastoid processes. Participants will be advised to use the device at home for 1 hour per day.

06

What researchers measure

Primary outcomes

  1. Insomnia Severity Index (ISI) score

    To evaluate the effect of the VeNS device, relative to control group on participants with insomnia. ISI is a self-report rating scale assessing the severity of insomnia symptoms (range 0-28) with higher scores indicating a more severe insomnia.

    Time frame: 4 weeks

Secondary outcomes

  1. Number of adverse events

    To evaluate the safety of the VeSTAL device relative to control group, in terms of the occurrence of adverse events.

    Time frame: 4 weeks

  2. Quality of life using SF-36 scores

    To evaluate the effect of the VeNS device, relative to control group, on quality of life. SF-36 is a 36-item short form survey (range 0-100) with higher scores indicating a better quality of life.

    Time frame: 4 weeks

  3. Quality of sleep using PSQI

    To evaluate the effect of the VeNS device, relative to control group, on quality of sleep quantified by change in the PSQI score. The sleep component scores are summed to yield a total score ranging from 0 to 21 with the higher total score indicating worse sleep quality.

    Time frame: 4 weeks

07

Study locations

2 sites
  • School of Nursing, The Hong Kong Polytechnic University
    Hung Hom, Kowloon HKSAR, Hong Kong
  • University of Ulster
    Coleraine, United Kingdom
08

References and documents

Individual participant data

Plan to share: No — Data will be transferred in an encrypted PDF format. Trial staff will be given direction on how to share the trial data and given access to one specific section of a controlled cloud service which is controlled via role based access. Once they have authenticated with the service and the service verifies that they have the correct role to access the system they will be directed to a single webpage within the application where they will be able to upload the encrypted PDF. This PDF is generated on the fly and is therefore not stored in another location that could become compromised. Generating the PDF on the fly means that the source data is extracted from the database, processed and delivered in the context of a single request. These data will be transferred for each subject when they complete participation in the study.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2022 to primary completion in Jan 2023, 6 months.

Of 78 industry-sponsored interventional studies with no phase under Sleep Initiation and Maintenance Disorders, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 23. This study's 6 months is close to that.

Counting every sponsor, half of 1,297 studies reached it within 15 months; a quarter within 6 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 26, 2020
First posted
Jul 1, 2020
StartActual
Jun 15, 2022
Primary completionActual
Jan 3, 2023
CompletionActual
Jan 3, 2023
Last update
Jan 16, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 16, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04452981
Lead sponsor
Neurovalens Ltd.
Collaborators
University of Ulster, The Hong Kong Polytechnic University
Responsible party
Sponsor
First posted
Jul 1, 2020
Start date
Jun 15, 2022
Primary completion
Jan 3, 2023
Completion
Jan 3, 2023
Last update
Jan 16, 2024

Study contacts

Julie Sittlington, PhD
principal investigator · University of Ulster

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion